{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:00:02Z","timestamp":1758636002218,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004386","name":"Universiti Malaya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.transproceed.2020.02.139","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T07:40:15Z","timestamp":1590046815000},"page":"1709-1714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience"],"prefix":"10.1016","volume":"52","author":[{"given":"Maisarah","family":"Jalalonmuhali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kok Peng","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Seong","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Wan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan Ahmad Hafiz","family":"Wan Md Adnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Kun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2020.02.139_bib1","first-page":"110","article-title":"Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage","volume":"4","author":"Malvezzi","year":"2015","journal-title":"J\u00a0Nephropathol"},{"key":"10.1016\/j.transproceed.2020.02.139_bib2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2215\/CJN.03800415","article-title":"Induction therapy in renal transplantation: Why? What agent? What dose? We may never know","volume":"10","author":"Wiseman","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2020.02.139_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1432-2277.2006.00270.x","article-title":"Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation","volume":"19","author":"Wong","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2020.02.139_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicentre, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2020.02.139_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104408","article-title":"Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study","volume":"9","author":"Grafals","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2020.02.139_bib6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/tri.12887","article-title":"De novo donor-specific anti- HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability","volume":"30","author":"Kauke","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2020.02.139_bib7","article-title":"Clinical significance of HLA-DQ antibodies in the development of chronic antibody-mediated rejection and allograft failure in kidney transplant recipients","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.transproceed.2020.02.139_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1399-3062.2009.00372.x","article-title":"Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation","volume":"11","author":"Fisher","year":"2009","journal-title":"Transpl Infect Dis"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134520301020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134520301020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:36:24Z","timestamp":1758576984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134520301020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0041134520301020"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2020.02.139","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2020.02.139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}